<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=us-ascii">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.EmailStyle18
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:507601307;
mso-list-template-ids:-1972874906;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1
{mso-list-id:1231647860;
mso-list-template-ids:-1000035812;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://announcements.fsu.edu/article/data-management-and-sharing-plans">NIH Data Management and Sharing Plans Virtual Workshop and Q&A</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The <a href="https://sharing.nih.gov/data-management-and-sharing-policy/about-data-management-and-sharing-policies" target="_blank">National Institutes of Health (NIH) have outlined new guidance</a> requiring
investigators to include a Data Management and Sharing Plan (DMSP) in proposals with submission deadlines <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-013.html" target="_blank">after January 25, 2023</a>. How does this affect your research?
What do you need to include in your DMSP? Join staff from the FSU Office of Research and the FSU Libraries for a workshop focused on crafting a DMSP that will meet policy requirements. Research Data Management Librarian, Dr. Nick Ruhs, will walk us through
the tools and resources you'll need while creating your DMSP. We'll have ample time for Q&A related to the new NIH guidance so that FSU researchers are prepared to respond. The live session will take place
<b>Thursday, January 19, 2023 from 10:30 a.m. – 12 p.m. via Zoom</b>. You may submit questions in advance when you
<a href="https://www.research.fsu.edu/research-offices/ord/events/2023-data-management-and-sharing-plans/">
Register Here</a>.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://klingenstein.org/klingenstein-third-generation-foundation/other-grants/applying/">Klingenstein Third Generation Foundation: Transformation of Mental Health Care</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The Klingenstein Third Generation Foundation is soliciting applications from academic investigators conducting research to demonstrate the benefits of novel ways to access or deliver mental health care
or prevention approaches that can be implemented at scale. This RFP is specifically for high quality research that builds upon promising pilot work and will lead to a larger demonstration project. Requests for service projects and applications that primarily
focus on expanding services will not be reviewed.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">In particular, KTGF is interested in improving access to high quality mental health care and prevention for children and adolescents through the use of novel models or promising approaches, including expanding
the number of professional and paraprofessional treatment personnel who are trained to deliver mental health services, delivering care in non-psychiatric settings (e.g., primary care, schools, home, or other novel settings), digital technology (e.g., the internet,
apps for cell phones), and approaches that help parents access care for their children.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The primary outcomes of the project include improved access and/or reduced time to service delivery, or implementation outcomes such as stakeholder involvement, acceptability, feasibility, and fidelity.
Primary outcomes should demonstrate that the project is being designed for scalability. Secondary outcomes include clinical or functional outcomes that are likely to improve when access to care is enhanced, such as decreased symptoms, burdens and maladaptive
behaviors associated with mental health problems; improved educational, relational and health outcomes; or enhanced youth and family functioning. 2-year projects; $100,000 per year.
<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due January 13, 2023. <span style="color:red">
Med-RA deadline to receive draft documents: January 3.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://www.hhmi.org/programs/biomedical-research/investigator-program">HHMI Investigator Program</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">HHMI Investigators do research that radically changes our understanding of how biology works, from molecular, biochemical and cellular processes to genetics, development and disease mechanisms, in a wide
range of organisms. These fundamental discoveries have been broadly recognized by the scientific community, including Nobel Prizes to more than 30 current or former Investigators. Investigators are appointed to a seven-year renewable term. Once appointed by
HHMI, Investigators:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-family:Palatino">Become employees of HHMI and receive their full salary and employee benefits from the Institute <o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-family:Palatino">Retain academic appointments and laboratories at their respective institutions <o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-family:Palatino">Receive generous financial support for research, as well as access to capital equipment funds <o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-family:Palatino">Belong to a community of more than 260 investigators and other HHMI scientists <o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-family:Palatino">Attend annual scientific meetings to share new research with other HHMI scientists <o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-family:Palatino">Appointments also involve a collaborative agreement between HHMI and the Investigator’s host institution, where the Investigator holds a concurrent appointment and maintains their research lab. Competition
opens in December. Check eligibility at <a href="https://www.hhmi.org/programs/biomedical-research/investigator-program#Eligibility">
https://www.hhmi.org/programs/biomedical-research/investigator-program#Eligibility</a>.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due March 21, 2023. <span style="color:red">
Med-RA deadline to receive draft documents: March 8.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-23-065.html">NIAID Resource-Related Research Projects (R24 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">This Funding Opportunity Announcement (FOA), issued by the National Institute of Allergy and Infectious Diseases (NIAID), invites applications for investigator-initiated Resource-Related Research Projects
(R24). The proposed resource must provide a significant benefit to currently funded high priority projects in need of further coordination and support in the areas specified. Under rare circumstances, this mechanism may be used to support development of a
new resource to the broader scientific community of the NIAID. It is anticipated that the request for resource support through the R24 activity code will occur on an infrequent basis and only in circumstances where other mechanisms of support from the NIAID
are not appropriate. The proposed resources should be relevant to the scientific areas of the NIAID mission including the biology, pathogenesis, and host response to microbes, including HIV; the mechanisms of normal immune function and immune dysfunction resulting
in autoimmunity, immunodeficiency, allergy, asthma, and transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious, immune-mediated, and allergic diseases.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Standard date apply. Expires January 8, 2026.
<b><span style="color:red">Med-RA deadline to receive draft documents for the January 25 standard date: January 11 (due to the Martin Luther King Jr. holiday).</span></b><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=344731">Distance Learning and Telemedicine Grants: Department of Agriculture, Rural Utilities Service</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The Distance Learning and Telemedicine Program provides financial assistance to enable and improve distance learning and telemedicine services in rural areas. DLT grant funds support the use of telecommunications-enabled
information, audio and video equipment, and related advanced technologies by students, teachers, medical professionals, and rural residents. These grants are intended to increase rural access to education, training, and health care resources that are otherwise
unavailable or limited in scope. Awards up to $1,000,000; ~100 proposals funded.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due January 30, 2023. <span style="color:red">
Med-RA deadline to receive draft documents: January 17.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-23-003.html">Pilot Projects Enhancing Utility and Usage of Common Fund Data Sets (R03 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Several valuable and widely available data sets have been generated by multiple Common Fund programs. The purpose of this funding opportunity announcement (FOA) is to announce the availability of funding
to demonstrate and enhance the utility of selected Common Fund (<a href="https://commonfund.nih.gov/">https://commonfund.nih.gov/</a>) data sets, including generating hypotheses and catalyzing discoveries. Award recipients are asked to provide feedback on
the utility of the Common Fund data resources.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due February 3, 2023. <span style="color:red">
Med-RA deadline to receive draft documents: January 23.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-22-256.html">Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) intends to accelerate the development of evidence-based cancer-related interventions that reflect the diversity
of people, places, contexts, and settings in the United States. Specifically, this FOA will support research that tests the impact of cancer-related interventions on cancer-related outcomes across the cancer control continuum using a pragmatic trial study
design. This FOA will use the UG3/UH3 phased cooperative agreement mechanism. The UG3 phase will support refining the cancer-related intervention and finalizing study-related activities in preparation for conducting the pragmatic trial during the UH3 phase.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due February 14, 2023; June 14, 2023; October 17, 2023; February 14, 2024; June 14, 2024; October 17, 2024; February 14, 2025; June 14, 2025; and October 17, 2025.
<span style="color:red">Med-RA deadline to receive draft documents for the February 14, 2023 due date: February 1.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://www.nsf.gov/pubs/2023/nsf23512/nsf23512.htm">NSF Using the Rules of Life to Address Societal Challenges (URoL:ASC)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Using the Rules of Life to Address Societal Challenges (URoL:ASC) will support use-inspired research that builds on knowledge from previous investments in the NSF "Big Ideas", including in the Understanding
the Rules of Life program. The Big Ideas were designed to position the Nation at the cutting edge of global science and engineering by bringing together diverse disciplinary perspectives to support convergent research (see details
<a href="https://www.nsf.gov/news/special_reports/big_ideas/life.jsp">here</a>). The goal of the
<i>Understanding the Rules of Life Big Idea was to develop</i> predictive understanding of how key properties of living systems emerge from interactions of factors such as genomes, phenotypes, and evolving environments. Examples of projects that have examined
some of these rules can be found <a href="https://www.nsf.gov/awardsearch/advancedSearchResult?ProgEleCode=106Y&BooleanElement=Any&BooleanRef=Any&ActiveAwards=true&#results">
here</a>. Following from the fundamental principles revealed from these and related projects, an important goal of the current solicitation is to use the predictive capability of rules of life to address some of the greatest challenges we currently face as
a society.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Through use-inspired research using
<a href="https://beta.nsf.gov/funding/learn/research-types/learn-about-convergence-research#definition">
convergent, multidisciplinary approaches</a>, URoL:ASC seeks to apply lessons learned from studying rules of life across a broad array of living systems to tackle pressing societal concerns. These concerns include but are not limited to: climate change and
associated risks, including geohazards, extreme events, and loss of biodiversity; environmental degradation, including impacts on land and water resources; inequalities in availability of and access to essential natural assets; lack of sustainability, including
for food, energy, and waste production; and threats from pandemic disease, among others.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due February 15, 2023.
<span style="color:red">Med-RA deadline to receive draft documents: February 2.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Mechanistic links between diet, lipid metabolism, and tumor growth and progression (UH2 / U01 Clinical Trial Not Allowed)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-23-052.html">UH2</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-23-051.html">U01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The purpose of these funding opportunity announcements is to request applications that propose mechanistic investigations of the links between diet, lipid metabolism and tumor growth and progression. It
is anticipated that this program will support fundamental studies designed to identify and define the molecular mechanisms through which lipid metabolism mediates tumor growth and progression, focusing specifically on the central role lipids play in linking
diet with the biology of cancer; bridge the historically divided fields of nutrition and molecular metabolism; and stimulate research and tool development in this emerging area, which faces particular challenges because of the complexity of lipid biochemistry.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due February 17, 2023; October 23, 2023; February 14, 2024; October 23, 2024; February 14, 2025; and October 23, 2025.
<span style="color:red">Med-RA deadline to receive draft documents for the February 17, 2023 due date: February 6.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://www.nsf.gov/pubs/2023/nsf23511/nsf23511.htm">NSF Biology Integration Institutes (BII)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Biology has transformed science over the last century through discoveries that cross subdisciplines from the molecular to the organismal to the ecosystem level. While making great progress, biology has
also slowly fragmented into subdisciplines, creating a dynamic tension between unifying principles and increasingly reductionist pursuits. The aim of this solicitation is to bring researchers together around the common goal of understanding how the processes
that sustain life and enable biological innovation operate and interact within and across different scales of organization, from molecules to cells, tissues to organisms, species, ecosystems, biomes and the entire Earth. The Biology Integration Institutes
(BII) program supports collaborative teams of researchers investigating questions that span multiple disciplines within and beyond biology.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Integration across biological disciplines is essential if we hope to understand the diverse and ever-increasing data streams of modern biology and tackle emergent questions about living organisms and the
environment. Of equal importance is the need for groundbreaking and sustainable training programs that prepare the next generations of scientists to navigate the breadth of biological sciences, training in multiple disciplines without sacrificing depth of
learning or innovation. In addition, the biology community must continue to develop practices and adopt strategies that leverage rapid advances in cyberinfrastructure and other technologies to bridge and integrate across subdisciplines and make resources accessible,
re-usable, and adaptable for unanticipated purposes. In these ways, Biology Integration Institutes will focus on biological themes that enable the discoveries of life’s innovations. The outcomes from biological integration will inspire new biotechnologies
and applications to drive our bioeconomy and provide solutions to societal challenges. While this solicitation focuses on the integration of
<b>biological </b>subdisciplines, any field beyond biology may be included as needed to address the overarching biological theme.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due February 21, 2023 and February 18, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for the February 21, 2023 due date: February 8.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-23-039.html">Development of Resources and Technologies for Enhancing Rigor, Reproducibility, and Translatability of Animal Models in Biomedical
Research (R24 Clinical Trials Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-23-039.html">R24</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The Office of Research Infrastructure Programs (<a href="https://orip.nih.gov">ORIP</a>) encourages resource-related research grant applications aimed at developing broadly applicable technologies, tools,
and resources for validating animal models and enhancing rigor, reproducibility, and translatability of animal research. Proposed studies, models, resources, or technologies submitted under this Funding Opportunity Announcement (FOA) must either address research
interests of multiple NIH Institutes and Centers (ICs), explore multiple organ systems, or be applicable to diseases and processes that impact multiple organ systems in order to align with
<a href="https://orip.nih.gov/strategic-plan">ORIP’s NIH-wide mission</a> and programs. Applications should aim to enhance the rigor, reproducibility, and translatability of animal research through the development of technologies, tools, and resources that
have significant impact across a broad range of research areas using animal models. Applications must demonstrate how the proposed resources and technologies impact rigor and reproducibility of animal studies. Applications for developing a limited quantity
of resources are not suitable for this FOA.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-23-040.html">R01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The Office of Research Infrastructure Programs (<a href="https://orip.nih.gov">ORIP</a>) encourages research project grant applications aimed at developing and implementing broadly applicable technologies,
tools, and resources for validating animal models and enhancing rigor, reproducibility, and translatability of animal research. Research projects submitted under this Funding Opportunity Announcement (FOA) should be hypothesis driven with strong preliminary
data. Proposed studies, models, resources, or technologies under this FOA must either address research interests of multiple NIH Institutes and Centers (ICs), explore multiple organ systems, or be applicable to diseases and processes that impact multiple organ
systems in order to align with <a href="https://orip.nih.gov/strategic-plan">ORIP’s NIH-wide mission</a> and programs. Applications should aim to enhance the rigor, reproducibility, and translatability of animal research through the development and implementation
of technologies, tools, and resources that have significant impact across a broad range of research areas using animal models. Applications must demonstrate how the proposed resources and technologies impact rigor and reproducibility of animal studies.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due February 24, 2023; standard dates beginning May 25, 2023. Expires May 26, 2025.
<span style="color:red">Med-RA deadline to receive draft documents for the February 24, 2023 due date: February 13.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-23-036.html">Secondary Analysis of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders (R21 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">This Funding Opportunity Announcement (FOA) encourages R21 applications that propose to conduct secondary analyses using existing human datasets in areas relevant to the National Heart, Lung, Blood Diseases
and Sleep Disorders Institute (NHLBI) scientific mission. The FOA aims to stimulate the use of existing human datasets to investigate novel scientific ideas, and/or generate new models, systems, tools, or technologies that have the potential for significant
impact on biomedical or biobehavioral research. Generation of new primary data is not allowed.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due February 28, 2023; October 28, 2023; February 28, 2024; October 28, 2024; February 28, 2025; and October 28, 2025.
<span style="color:red">Med-RA deadline to receive draft documents for the February 28, 2023 due date: February 15.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-23-041.html">Functional Validation and/or Characterization of Genes or Variants Implicated in Substance Use Disorders (R21/R33 Clinical Trial Not
Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The purpose of this initiative is to support projects that functionally validate and/or characterize genes or variants involved in substance use disorder-relevant phenotypes.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due March 2, 2023; July 26, 2023; March 4, 2024; July 26, 2024; March 3, 2025; and July 28, 2025.
<span style="color:red">Med-RA deadline to receive draft documents for the March 2 due date: February 17.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Targeting Inflammasomes in Substance Abuse and HIV (R21 / R01 Clinical Trial Not Allowed)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-004.html">R21</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-003.html">R01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The scientific objective of these Funding Opportunity Announcements (FOAs) is to encourage research to explore mechanisms of inflammasome activation, humoral immune reaction and potential antibody-mediated
enhancement, and their link to immune functions in people with HIV and substance use disorders (SUDs). These FOAs support studies to either (1) elucidate the mechanisms of inflammasomes in virus and drug-induced immune activation, or (2) identify molecular
markers and CNS immune cells associated with HIV-1 infection or disease progression among individuals with SUD. Success of these projects may lead to development of novel therapies that target inflammasome activation or suppression to treat neuroinflammation
and immune dysregulation aroused in these processes.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due March 15, 2023. <span style="color:red">
Med-RA deadline to receive draft documents: March 2.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-24-006.html">Using Archived Data and Specimen Collections to Advance Maternal and Pediatric HIV/AIDS Research (R21 - Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The purpose of this Funding Opportunity Announcement (FOA) is to utilize archived HIV/AIDS data and biospecimen collections to generate new research questions and findings related to epidemiology, pathogenesis,
treatment, prevention, clinical manifestations, and HIV-associated co-infections in maternal, pediatric, and adolescent populations.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due March 29, 2023. <span style="color:red">
Med-RA deadline to receive draft documents: March 16.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Ancillary Studies to Ongoing Clinical Projects (R21 / R01 Clinical Trial Not Allowed)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-23-026.html">R21</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-23-025.html">R01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">These Funding Opportunity Announcements (FOAs) solicit applications that propose to conduct time-sensitive ancillary studies related to the NIAMS mission in conjunction with privately or publicly funded,
active, ongoing clinical projects (parent projects). The parent project can be an interventional clinical trial, or a clinical study such as an observational study, or a disease-specific repository that will be actively collecting patient samples or clinical
data. The parent project(s) should provide a cohort of well-characterized patients, infrastructure, data, and biological samples for the ancillary study. Applications submitted in response to these FOAs will undergo an accelerated review and award process.
The objective of these FOAs is to provide a flexible mechanism to leverage currently funded resources and maximize the return on existing investments in parent projects. Successful ancillary studies will enhance the scientific content and value of the parent
projects, improve the research community’s understanding of a disease or organ system in the NIAMS portfolio, and thus may identify novel targets for diagnosis, treatment, and prevention of disease.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due April 6, 2023; August 7, 2023; December 6, 2023; April 4, 2024; August 6, 2024; December 6, 2024; April 9, 2025; August 6, 2025; and December 5, 2025.
<span style="color:red">Med-RA deadline to receive draft documents for the April 6, 2023 due date: March 24.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Research Infrastructure Development for Interdisciplinary Aging Studies (R33 and R61/R33 - Clinical Trial Optional)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-23-054.html">R33</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-23-053.html">R61/R33</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">These Funding Opportunity Announcements invite applications that propose to develop novel research infrastructure that will advance the science of aging in specific areas requiring interdisciplinary partnerships
or collaborations. Through this award, investigators will endeavor to develop a sustainable research infrastructure to support projects that address key interdisciplinary aging research questions.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due July 3, 2023; November 2, 2023; July 2, 2024; November 4, 2024; July 2, 2025; and November 3, 2025.
<span style="color:red">Med-RA deadline to receive draft documents for the July 3, 2023 due date: June 20.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
</div>
</body>
</html>